Search ACOR  Site Contents: • Types of Leukemia • Living with Leukemia • Transplants • Blood & Pathology • Survivor Stories • Medical & Cancer Links • Internet Support Email Lists • Resources • Leukemia Links Site Map Online Resources for CML  Contents General Information Journal articles and abstracts Other Articles Adult CML Patient Stories Childhood CML Patient Stories In Loving Memory of those who passed away from this terrible disease. Information on subscribing to the CML mailing list Information on subscribing to the BMT-Talk mailing list  General Information about CML The NCI PDQ patient statement on chronic myelogenous leukemia . The NCI PDQ physician statement on chronic myelogenous leukemia . BMTs for Chronic Myelogeneous Leukemia from BMT Newsletter , March 1995, Issue #28. The CML Frequently Asked Questions list (FAQ) from the MPD-NET page . Chronic Myelogenous Leukemia (CML) a booklet from the Leukemia and Lymphoma Society of America which aims to provide information about CML to patients and their families. In Spanish: Leucemia Mieloide Crónica . Understanding Chronic Myeloid Leukaemia (CML) a basic introduction to CML from CancerBACUP an organization in England that aims to help people live with cancer by providing information, emotional support and counselling. The University of Newcastle CML site, by Stephen G. O'Brien. This site has a lot of information on the drug STI571, the Royal Victoria Infirmary in Newcastle was the first UK center to this drug. Chronic Myelogenous Leukemia by Emmanuel C Besa, MD and Ulrich Woermann, MD, from the eMedicine World Medicine Library . This is a very technical review of the symptoms, causes, diagnosis and treatment of CML. Chronic Myeloid Leukemia from CancerConsultants.com is an overview of the treatment of CML for patients.  Journal Articles about CML Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia by Hughes, T.P., et. al., New England Journal of Medicine , Vol. 349, No. 15: October 9, 2003, pages 1423-1432. 1106 patients with CML in chronic phase were randomized to Imatinib (Gleevec) or Interferon Alfa plus cytarabine as initial therapy. After 12 months 68 percent of the Imatinib had a complete cytogenetic response (no evidence of chromosomal abnormalities) versus 7 percent in the Interferon group. 39 percent of the Imatinib group versus 2 percent of the Interferon group had a reduction of BCR-ABL transcript levels of more then 1000 times. For those patients, 100 percent were still in remission after 24 months. Chronic Myelogenous Leukemia , Brian J. Druker, Charles L. Sawyers, Renaud Capdeville, John M. Ford, Michele Baccarani and John M. Goldman Hematology , American Society of Hematology Education Program Book , 2001. The treatment of CML is evolving rapidly since the introduction of STI-571 (Gleevec, imatinib mesylate), and the use of non-myeloablative stem cell transplants ("mini-PBSCT"). This articles provides an overview of the resutls using STI-571 as well as an overview on administering it, including management of common side effects and interactions with other drugs. In addition, recent results using Interferon and stem cell transplants are presented. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia by Kantarjian, H., et. al., New England Journal of Medicine , Vol. 346, No. 9: February 28, 2002, pages 645-652. (The full article is available for free 6 months after publication, the article abstract is available now.) 532 patients with late-chronic-phase CML who had failed interferon alfa treated were treated with oral Imatinib Mesylate (STI-571, Gleevec). Imatinib induced major cytogenetic responses in 60 percent of patients and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed in an estimated 89 percent of patients, and 95 percent of the patients were alive. Major-Histocompatibility-Complex Class I Alleles and Antigens in Hematopoietic-Cell Transplantation by Petersdorf, E.W., et. al., New England Journal of Medicine , Vol. 345, No. 4, July 26, 2001, pages 241-247. (The full article is available for free 6 months after publication, the article abstract is available now.) This article reports on a study of a large number of MUD transplants for CML done at the Fred Hutchinson Cancer Research Center . It looked at whether HLA mismatches that are detectable only at the DNA level are associated with a lower risk of graft failure then mismatches that are detectable by serology. The risk of graft failure in patients with a donor with an HLA mismatch that is detectable only at the DNA level is not increased compared with patients with a donor with no mismatches. Efficacy and Safety of a Specific Inhibitor of the BCR-aBL Tyrosine Kinase in Chronic Myeloid Leukemia , from the New England Journal of Medicine april 5, 2001, Vol. 344, No. 14, pages 1031-1037, by Brian J. Druker, et. al. (registration, which is free is required). Reports on the a Phase I trial of STI-571 (Gleevec) in the treatment of 83 patients with CML in the chronic phase. Most patients responded to STI-571 including some who experienced a completer remission. another article in the same edition, page 1038-1042 is activity of a Specific Inhibitor of the BCR-aBL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and acute Lymphoblastic Leukemia with the Philadelphia Chromosome by Brian J. Druker, et. al, reports on STI-571 in patients in Blast Crisis (and also some patients with ALL who have the Philadelphia chromosome). also an accompanying editorial Targeting the BCR-aBL Tyrosine Kinase in Chronic Myeloid Leukemia by John M. Goldman, and Junia V. Melo. Anagrelide for Treatment of Patients with Chronic Myelogenous Leukemia and a High Platelet Count , Trapp, O.M.,beykirch, M.K., Petrides, P.E., from blood Cells, Molecules, & Diseases, Issue 2, Vol. 24: January 31, 1998. The article abstract as well as the entire article in PDF format are available. Recent Experience with bone marrow transplants in Adults recieving HLA-Identical Related Transplants for CML , from the Fred Hutchinson Cancer Research Center . < Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia , from the New England Journal of Medicine april 2, 1998, Vol. 338, No. 14, pages 962-968, by John a. Hansen,, et. al. (registration, which is free is required). , reports on the experience at the Fred Hutchison Cancer Center with matched unrelated donor (MUD) BMTs for CML. also an accompanying editorial a Chance of Cure for Every Patient with Chronic Myeloid Leukemia? by Rudiger Hehlman in the same edition. Interferon alfa-2b Combined with Cytarabine versus Interferon alone in Chronic Myelogenous Leukemia , from the New England Journal of Medicine July 24, 1997, Vol. 337, No. 4, pages 223-229, by Francois Guilhot, et. al. (registration, which is free is required). Reports on the experience from the French Chronic Myeloid Leukemia Study Group with Interferon alone and Interferon combine with low dose monthly courses of Cytarabine (ara-C). also an accompanying editorial Optimizing Treatment for Chronic Myeloid Leukemia by John M. Goldman in the same edition and followup correspondence from the November 27, 1997, Vol 337, No 22 issue. ABC of clinical haematology: Chronic myeloid leukaemia , a review article by John Goldman, from the British Medical Journal , Vol 314, page 657, 1 March 1997. Survival with Bone Marrow Transplantation Versus Hydroxyurea or Interferon for Chronic Myelogenous Leukemia: The German CML Study Group , article abstract from Blood Volume 91, No. 5, pages 1810-1819, 1998 along with an Editorial Commment by Hussain I. Saba, MD, PhD from Medscape . Chronic Myelogenous Leukemia: Biology and Therapy Faderl, S, et. al., Annals of Internal Medicine, 3 August 1999. 131:207-219. This article provides an overview of the diagnosis, current and future treatment options and prognosis for CML. Current Status of Treatment for Chronic Myelogenous Leukemia , by Kolibaba, K. and Druker, B., from Medscape Oncology . Discusses the diagnosis of CML and the current treatment options, including Interferon Alpha, bone marrow transplants, Hydroxyurea, Busulfan, Cytarabine and experimental agents Homoharringtonine (HHT) and STI 571.  Other Articles Oregon Cancer Center - Leukemia Program , part of the The Oregon Cancer Center , Portland, Oregon. Brian Druker is the program leader of the Hematologic Malignancies Program and this site contains information about STI-571 (Gleevec). Gleevec information from Novartis, the manufactor of Gleevec® (imatinib mesylate), includes a information on CML, a Frequently Asked Question (FAQ) section and a glossary. Glivec information is another site by Novartis for Healthcare Professionals outside the U.S. It seems to contain more scientific information on Gleevec and Información sobre Glivec. Alpha Interferon in the Treatment of Chronic Myeloid Leukaemia . Report No. 52, March, 1996 from the Development and Evaluation Committee of the National Health Service South & West Research & Development Directorate, UK. . A warning about interferon , an article the Fred Hutchinson Cancer Research Center, Center News , about research reported at American Society of Hematology annual meeting, in December, 1997. This study lead by Dr. Claudio Anasetti, looked at survival rates of patients with CML had undergone treatment with interferon alpha prior to having a unrelated marrow transplant. The original article is: impact of pre-transplant interferon-α on outcome of unrelated donor marrow transplants for chronic myeloid leukemia in first chronic phase (article abstract only). Polyethylene Glycol (PEG) Intron from Leukemia Insights , a quarterly newsletter written primarily for physician, published by M D anderson Cancer Center , University of Texas Medical Center, Houston, TX. Guidelines for the Management of CML with Interferon alpha from Leukemia Insights Newsletter , a quarterly newsletter written primarily for physician, published by M D anderson Cancer Center , University of Texas Medical Center, Houston, TX. New Therapy Discovered For One Of Most Common Leukemias , a press release on the results of the Phase I clinical trial of STI 571 for CML patients in chronic phase. This is discusses the articles by Druker, et. al. from the American Society of Hematology (ASH) 1999 annual meeting. The abstracts from the ASH conference are available here . More information on STI 571 is available from the unofficial STI 571 site (which is not associated with Novartis the makers of STI 571). Information on the enrolling in clinical trials of STI 571 is available from Novartis . HOME  ::  ABOUT THIS SITE  ::  CONTACT Last updated: November 7, 2005 Copyright ©2004, 2005 ACOR, Inc. All worldwide rights reserved. ACOR and ACOR.org are registered trademarks of the Association of Online Cancer Resources, Inc.